MedTrace Logo

Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy

NCT06302608 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-03-12

No results posted yet for this study

Summary

Evaluate the safety and tolerability of NGGT001 subretinal injection for the treatment of crystalline retinal degeneration (BCD)

Conditions

  • Bietti's Crystalline Dystrophy

Interventions

GENETIC

NGGT001

Safety and Effectiveness of subretinal injection of NGGT001 for treating crystalline retinal degeneration

Sponsors & Collaborators

  • Xiamen Ophthalmology Center Affiliated to Xiamen University

    lead OTHER

Principal Investigators

  • Li · Xiamen Ophthalmology Center Affiliated to Xiamen University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-08
Primary Completion
2024-05-29
Completion
2028-05-29

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06302608 on ClinicalTrials.gov